For the Quarter Ending March 2026
Epinephrine Prices in North America
- In United States, the Epinephrine Price Index rose quarter-over-quarter in Q1 2026, driven by tightened supply and manufacturing delays.
- During March 2026, consumer inflation reached 3.3% year-over-year, while producer prices rose 4.0%, elevating the Epinephrine Production Cost Trend.
- The Manufacturing Index expanded in March 2026, alongside a 0.7% year-over-year industrial production increase, supporting steady pharmaceutical output.
- Retail sales grew 4.0% year-over-year in March 2026, while unemployment held at 4.3%, sustaining a strong Epinephrine Demand Outlook.
- Consumer confidence reached a 91.8 index in March 2026, encouraging consistent prescription renewals and supporting the Epinephrine Price Index.
- Pharmaceutical demand for epinephrine strengthened in Q1 2026, driven by rising incidences of severe allergic and chronic respiratory diseases.
- Epinephrine auto-injector availability remained constrained in Q1 2026, with intermittent regional stockouts persisting across the healthcare sector.
- The Epinephrine Price Forecast indicated upward pressure throughout Q1 2026 due to persistent backorders from major producers.
Why did the price of Epinephrine change in March 2026 in North America?
- Epinephrine injection supply tightened in Q1 2026 due to ongoing manufacturing delays and persistent backorders.
- Producer prices increased 4.0% year-over-year in March 2026, pushing up pharmaceutical synthesis and assembly costs.
- Strong retail sales in March 2026 sustained high consumer purchasing power for emergency allergy medications.
Epinephrine Prices in APAC
- In China, the Epinephrine Price Index rose quarter-over-quarter in Q1 2026, driven by surging healthcare demand.
- The Epinephrine Production Cost Trend increased as factory-gate prices rose 0.5% year-over-year in March 2026.
- The Epinephrine Demand Outlook strengthened alongside a 1.0% year-over-year consumer inflation increase in March 2026.
- Industrial production grew 5.7% year-over-year in March 2026, ensuring steady upstream chemical reagent and packaging manufacturing.
- Higher unemployment at 5.4% and 1.7% retail sales growth constrained discretionary pharmacy spending in March 2026.
- A low consumer confidence index of 91.6 in February 2026 limited preventative auto-injector stocking purchases.
- The Manufacturing Index expanded in March 2026, supporting robust pharmaceutical packaging and medical device assembly.
- Epinephrine demand surged due to urbanization-driven allergies and expanded government healthcare reforms in March 2026.
- Production costs for methylamine stabilized as upstream ammonia supply remained adequate across China in February 2026.
- The Epinephrine Price Forecast stabilized as active pharmaceutical ingredient safety stocks expanded significantly in March 2026.
Why did the price of Epinephrine change in March 2026 in APAC?
- Surging urbanization-driven allergies and expanded government healthcare reforms elevated domestic Epinephrine consumption in March 2026.
- Factory-gate prices rose 0.5% year-over-year, directly increasing upstream chemical precursor procurement costs in March 2026.
- Catechol exports faced severe maritime shipping disruptions in the Strait of Hormuz during March 2026.
Epinephrine Prices in Europe
- In Germany, the Epinephrine Price Index rose quarter-over-quarter in Q1 2026, driven by surging methanol feedstock costs.
- The Epinephrine Production Cost Trend increased in March 2026 as broader energy costs surged alongside 2.7% CPI inflation.
- The Epinephrine Demand Outlook stabilized in Q1 2026 despite a 4.0% unemployment rate and -2.0% retail sales decline.
- Pharmaceutical sector methanol feedstock sales stabilized in Q1 2026, contrasting with 0.0% industrial production and -0.2% PPI deflation.
- The Manufacturing Index contracted in March 2026, aligning with deeply negative consumer confidence at -24.7, impacting broader markets.
- Methanol feedstock inventories for Epinephrine lengthened in January 2026, while overall supply remained long during the same period.
- Phenol feedstock demand weakened in February 2026, and methanol feedstock trade flows experienced disruptions in March 2026.
- The Epinephrine Price Forecast indicated upward pressure in Q1 2026 due to rising phenol feedstock costs in February.
Why did the price of Epinephrine change in March 2026 in Europe?
- Methanol feedstock costs for Epinephrine surged in March 2026, driving up overall regional production expenses.
- Broader energy costs impacting Epinephrine feedstocks surged in March 2026, adding significant upward market pressure.
- Methanol feedstock trade flows for Epinephrine experienced disruptions in March 2026, tightening regional supply availability.
For the Quarter Ending December 2025
Epinephrine Prices in North America
- In United States, the Epinephrine Price Index rose quarter-over-quarter in Q4 2025, driven by rising production costs and strengthened pharmaceutical market.
- Epinephrine production costs rose from a 2.7% CPI increase in December 2025 and a 3.0% PPI increase in November 2025.
- Natural gas prices strengthened in late Q4 2025, contributing to higher energy expenses for Epinephrine production.
- Epinephrine demand was supported by strengthened pharmaceutical market performance in Q4 2025 and steady novel drug introductions in October 2025.
- US biopharmaceutical manufacturing investment remained robust in Q4 2025, supporting supply chain stability.
- Chlorine feedstock costs weakened in November 2025, offering some relief to Epinephrine production expenses.
- A 4.4% unemployment rate in December 2025 and 3.3% retail sales growth in November 2025 supported demand.
- Industrial production increased 2.0% in December 2025; consumer confidence at 89.1 supported a stronger economy.
Why did the price of Epinephrine change in December 2025 in North America?
- Rising input costs, with CPI up 2.7% in December 2025, elevated Epinephrine raw material and labor.
- Producer costs for Epinephrine climbed, PPI up 3.0% in November 2025, reflecting higher manufacturing inputs.
- Strengthened pharmaceutical market performance in Q4 2025 and robust biopharmaceutical investment supported Epinephrine demand.
Epinephrine Prices in APAC
- In China, the Epinephrine Price Index remained stable quarter-over-quarter in Q4 2025, influenced by mixed macroeconomic signals.
- Epinephrine production costs declined in December 2025, as the Producer Price Index fell by 1.9% year-on-year.
- Demand for Epinephrine faced headwinds in December 2025, with retail sales growth weakening to 0.9% year-on-year.
- The Manufacturing Index expanded in December 2025, indicating robust industrial activity and stable supply chains.
- Industrial production advanced by 5.2% year-on-year in December 2025, supporting overall economic health and pharmaceutical distribution.
- Input cost inflation for manufacturing accelerated in December 2025, driven by higher raw material prices and crude oil support.
- Chinese companies increased injectable drug exports in 2025, responding to strong demand in high-regulation markets.
- The Consumer Price Index rose by 0.8% year-on-year in December 2025, reflecting subdued inflationary pressures.
Why did the price of Epinephrine change in December 2025 in APAC?
- Producer Price Index declined by 1.9% year-on-year in December 2025, reducing Epinephrine production costs.
- Weakened retail sales growth of 0.9% year-on-year in December 2025 indicated subdued consumer demand.
- Input cost inflation accelerated in December 2025, driven by higher raw material prices and crude oil support.
Epinephrine Prices in Europe
- In Germany, the Epinephrine Price Index fell in Q4 2025, primarily due to decreasing producer input costs.
- Epinephrine production costs declined in December 2025 as the Producer Price Index decreased 2.5% year-over-year.
- Overall consumer inflation, measured by CPI, was 1.8% year-over-year in December 2025, influencing operational expenses.
- The Manufacturing Index contracted in December 2025, indicating a slowdown in broader industrial activity.
- Industrial production showed modest 0.8% year-over-year growth in October 2025, supporting manufacturing stability.
- Epinephrine demand outlook faced headwinds from 6.2% unemployment in December 2025, impacting healthcare budgets.
- Consumer confidence remained pessimistic at -17.5 in December 2025, reflecting broader economic anxieties.
- Vulnerabilities in pharmaceutical supply chains were ongoing in late 2025, affecting Epinephrine availability.
- Germany's gas storage facilities met targets by October and November 2025, stabilizing energy feedstock costs.
- Healthcare sector M&A activity remained highly active in Q4 2025, with transaction momentum accelerating.
Why did the price of Epinephrine change in December 2025 in Europe?
- Epinephrine production costs declined in December 2025, as PPI fell 2.5% year-over-year.
- The Manufacturing Index contracted in December 2025, indicating a broader industrial slowdown.
- Pharmaceutical supply chain vulnerabilities persisted in late 2025, impacting Epinephrine availability.
For the Quarter Ending September 2025
Epinephrine Prices in North America
- In United States, the Epinephrine Price Index rose quarter-over-quarter in Q3 2025, driven by increasing producer-level costs.
- Epinephrine production costs increased due to a 3.0% CPI rise in September 2025, impacting overall operational expenses.
- Producer-level costs for Epinephrine manufacturing rose by 2.6% year-over-year in August 2025, affecting raw material prices.
- Demand for Epinephrine remained robust in 2025, supported by accelerating national health expenditures in the healthcare sector.
- Prescription drug spending showed a sustained increase in 2025, bolstering the Epinephrine demand outlook.
- US industrial production saw a marginal 0.1% year-over-year increase in September 2025, indicating slow sector growth.
- The broader US chemical industry experienced persistent overcapacity in Q3 2025, influencing general supply dynamics.
- Natural gas prices, a key energy feedstock for chemical production, settled lower in September 2025.
- An inventory glut in the chemical industry during Q3 2025 contributed to broader oversupply conditions.
Why did the price of Epinephrine change in September 2025 in North America?
- Rising producer costs, evidenced by a 2.6% PPI increase in August 2025, pressured Epinephrine manufacturing expenses.
- Increased consumer-level inflation, with CPI up 3.0% in September 2025, elevated Epinephrine operational costs.
- Sustained demand for prescription drugs in 2025 supported Epinephrine market stability despite broader chemical overcapacity.
Epinephrine Prices in APAC
- In China, the Epinephrine Price Index fell quarter-over-quarter in Q3 2025, influenced by declining production costs and deflationary pressures.
- Epinephrine production costs declined in Q3 2025, as the Producer Price Index fell by 2.3% in September 2025.
- Methylamine feedstock costs, a key input, decreased in China during Q3 2025 due to persistent oversupply.
- Demand for Epinephrine remained stable in Q3 2025, supported by robust industrial production growth of 6.5% in September 2025.
- Stable retail sales, increasing by 3.0% in September 2025, indirectly supported healthcare funding and access to medicines.
- Deflationary pressures, with CPI falling by 0.3% in September 2025, exerted downward influence on pharmaceutical pricing.
- Elevated methylamine inventories accumulated in China during Q3 2025, reflecting broader chemical industry oversupply.
- The Manufacturing Index contracted in September 2025, signaling broader economic weakness impacting the sector.
Why did the price of Epinephrine change in September 2025 in APAC?
- Declining Producer Price Index by 2.3% in September 2025 reduced manufacturing input costs.
- Methylamine feedstock costs decreased in Q3 2025 due to oversupply, lowering production expenses.
- Deflationary Consumer Price Index of -0.3% in September 2025 created downward pressure on pharmaceutical prices.
Epinephrine Prices in Europe
- In Germany, the Epinephrine Price Index remained stable quarter-over-quarter in Q3 2025, reflecting balanced market pressures.
- Production costs faced downward pressure from a 1.7% year-over-year PPI decline in September 2025.
- However, broader inflationary pressures, with CPI rising 2.4% year-over-year in September 2025, impacted input costs.
- Demand outlook was tempered by Germany's industrial production declining 1.0% year-over-year in September 2025.
- Despite a contracting Manufacturing Index in September 2025, pharmaceutical sector output firmed, showing resilience.
- Elevated electricity prices for businesses in Q3 2025 continued to pressure Epinephrine production expenses.
- Chemical industry inventories shrank in Q3 2025 due to accelerating destocking, influencing supply dynamics.
- A low unemployment rate of 3.9% in September 2025 supported consumer affordability for essential healthcare.
- The Epinephrine price forecast suggests continued stability, balancing cost pressures against weak overall demand.
Why did the price of Epinephrine change in September 2025 in Europe?
- Deflationary producer prices, down 1.7% year-over-year in September 2025, reduced Epinephrine production costs.
- Elevated electricity prices for businesses in Q3 2025 pressured overall Epinephrine production expenses.
- Weakened chemical demand and declining industrial production in Q3 2025 limited Epinephrine price increases.
For the Quarter Ending December 2022
North America
- Over the first half of the fourth quarter, Epinephrine prices gradually increased at a moderate rate in North America. End-user demand from the pharmaceutical industry kept Epinephrine costs on the sturdy end.
- Additionally, there was a steep decline in supply chain disruption in the six months leading up to November across several measures, including shipping costs, which further strengthened the Epinephrine market in an upward direction.
- However, towards the end of q4, they started to fall precipitously due to a major decrease in their offtakes and New year breaks. Prices for Epinephrine stayed on the North side, with the settlement at USD 2448000 /MT CFR Los Angeles.
APAC
In the fourth quarter of 2022, Epinephrine prices in the Asia Pacific area, particularly in China, plummet by the end of December. However, prices remained on the upper side throughout the initial half of q4 due to increased downstream demand balanced with adequate supplies among market participants. On the other hand, the ease in supply chain disruption in November compared to October, including the lower shipping costs, encouraged the traders and suppliers to raise their quotations. With the year ending 2022 concluding, China's production activities started to decline, particularly after November, due to an increase in COVID-19 instances and a reduction in freight costs, supporting Epinephrine's price trend in China. Overall, the Epinephrine costs noted in the middle of the fourth were assembled at USD 2318500/MT FOB Shanghai in China.
Europe
The Epinephrine market in Europe followed a similar trajectory to that in Asia Pacific in the fourth quarter of 2022. Due to a rise in demand from the end-user pharmaceutical business, the market trend started off well up until November and reached an assembly price of USD 2491500/MT CFR Hamburg in Germany. After November, Epinephrine inquiries from the downstream industry started to decline dramatically, which reinforced the drug's weaker price trend because market participants had plenty of supply and little to no demand. Also, fresher quotations declined in December because of suppliers' high stock levels brought on by the market closure.
